Bridge to Life™ Advances Transplant Science with HOPE Findings
Pivotal Findings Spotlighted in Plenary Session, Late-Breaking Presentations, and Symposium on Next-Gen Liver Preservation
Bridge to Life™ Ltd. has recently presented significant clinical data at the World Transplant Congress (WTC), held in connection with prestigious organizations dedicated to advancing organ transplantation. The focal point of the presentations was the 12-month follow-up results from the groundbreaking Bridge to HOPE trial, which emphasized the transformative effects of hypothermic oxygenated perfusion (HOPE) in liver transplantation.
Highlights from the Presentations
During this prominent event, Bridge to Life's findings were showcased through various oral presentations and late-breaking abstracts, affirming the company's commitment to enhancing transplant science.
Plenary Session Insights
As a key part of the conference, the Plenary Session featured the presentation titled, "Hypothermic-Oxygenated and Normothermic Machine Perfusion: A Risk-Matched Post-Hoc Comparison of the Bridge to Hope Randomized Trial with Prospectively Collected Institutional Outcomes." This session was presented by Dr. Chase J. Wehrle from the Cleveland Clinic, highlighting the significant outcomes achievable through hypothermic perfusion.
Poster Presentations Overview
Several insightful poster presentations were also on display, including topics such as the impact of hypothermic oxygenated machine perfusion on ischemia-reperfusion injury in liver transplantation, led by Dr. Marco Maria Pascale from Fondazione Policlinico Universitario Agostino Gemelli. Another notable poster addressed mitochondrial injury during liver preservation, reflecting ongoing research into optimizing liver perfusion processes.
Oral Abstract Presentations
The conference also featured compelling oral abstract presentations. An abstract titled, "Economic Assessment of Hypothermic Oxygenated Machine Perfusion in Liver Transplantation," presented by Dr. David Axelrod, explores the cost benefits of these advanced technologies in clinical settings. Moreover, another presentation reviewed the severity of rejection instances linked to hypothermic oxygenated perfusion, based on multicenter trial data.
Late-Breaking Abstracts
Late-breaking abstracts featured ground-breaking titles such as "Novel Approach to Viability Assessment of Split Liver Grafts Using Hypothermic Oxygenated Perfusion," presented by Dr. Geofia Crasta. These findings contribute to understanding the viability of organs before transplantation, potentially enhancing graft survival rates.
Symposium Featuring Leading Experts
In conjunction with these presentations, Bridge to Life™ will sponsor a symposium aiming to deepen the understanding of hypothermic oxygenated perfusion's clinical impact. Scheduled moderators and speakers are experts from various esteemed institutions, showcasing a collaborative approach to enhancing liver transplant procedures and patient outcomes.
The symposium is set for the morning, inviting attendees to engage in discussions about the latest advancements in liver preservation techniques.
About Bridge to Life™ Ltd
As a leading entity in organ preservation, Bridge to Life™ Ltd has established a reputable standing through its premier products like Belzer UW®, EasiSlush®, and the innovative VitaSmart™ Hypothermic Oxygenated Perfusion System. The company's dedication to quality and innovation is evident as it partners with key transplant centers and organ procurement organizations worldwide.
While VitaSmart™ is already CE Marked and sold in various international markets, it awaits FDA approval for distribution within the United States, marking a significant milestone for the company and enhancing the accessibility of its pioneering technologies.
Frequently Asked Questions
What is the Bridge to HOPE trial?
The Bridge to HOPE trial investigates the effects of hypothermic oxygenated perfusion on liver transplantation and its long-term impacts on recipients.
What were the main findings presented at the World Transplant Congress?
Key findings include improvements in clinical outcomes and economic benefits associated with using hypothermic oxygenated perfusion in liver transplantation.
Who presented at the plenary session?
Dr. Chase J. Wehrle from the Cleveland Clinic presented significant research comparing hypothermic and normothermic machine perfusion techniques.
What is the role of Bridge to Life™ in organ preservation?
Bridge to Life™ specializes in developing advanced organ preservation solutions, enhancing organ viability and transplant outcomes.
When is the symposium hosted by Bridge to Life™?
The symposium is scheduled for the morning on August 4, focusing on translating scientific findings into clinical practice in liver transplantation.
